330 related articles for article (PubMed ID: 36278234)
1. Farnesoid-X receptor as a therapeutic target for inflammatory bowel disease and colorectal cancer.
Zhou M; Wang D; Li X; Cao Y; Yi C; Wiredu Ocansey DK; Zhou Y; Mao F
Front Pharmacol; 2022; 13():1016836. PubMed ID: 36278234
[TBL] [Abstract][Full Text] [Related]
2. Bile acid nuclear receptor FXR and digestive system diseases.
Ding L; Yang L; Wang Z; Huang W
Acta Pharm Sin B; 2015 Mar; 5(2):135-44. PubMed ID: 26579439
[TBL] [Abstract][Full Text] [Related]
3. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease.
Gadaleta RM; van Erpecum KJ; Oldenburg B; Willemsen EC; Renooij W; Murzilli S; Klomp LW; Siersema PD; Schipper ME; Danese S; Penna G; Laverny G; Adorini L; Moschetta A; van Mil SW
Gut; 2011 Apr; 60(4):463-72. PubMed ID: 21242261
[TBL] [Abstract][Full Text] [Related]
4. Intestine-specific FXR agonists as potential therapeutic agents for colorectal cancer.
Yin Y; Wang M; Gu W; Chen L
Biochem Pharmacol; 2021 Apr; 186():114430. PubMed ID: 33556338
[TBL] [Abstract][Full Text] [Related]
5. SUMOylation of the farnesoid X receptor (FXR) regulates the expression of FXR target genes.
Balasubramaniyan N; Luo Y; Sun AQ; Suchy FJ
J Biol Chem; 2013 May; 288(19):13850-62. PubMed ID: 23546875
[TBL] [Abstract][Full Text] [Related]
6. Ablation of liver
Ijssennagger N; van Rooijen KS; Magnúsdóttir S; Ramos Pittol JM; Willemsen ECL; de Zoete MR; Baars MJD; Stege PB; Colliva C; Pellicciari R; Youssef SA; de Bruin A; Vercoulen Y; Kuipers F; van Mil SWC
JHEP Rep; 2021 Oct; 3(5):100344. PubMed ID: 34604725
[TBL] [Abstract][Full Text] [Related]
7. Transcriptional regulation of the intestinal nuclear bile acid farnesoid X receptor (FXR) by the caudal-related homeobox 2 (CDX2).
Modica S; Cariello M; Morgano A; Gross I; Vegliante MC; Murzilli S; Salvatore L; Freund JN; Sabbà C; Moschetta A
J Biol Chem; 2014 Oct; 289(41):28421-32. PubMed ID: 25138215
[TBL] [Abstract][Full Text] [Related]
8. Farnesoid X Receptor Agonist Treatment Alters Bile Acid Metabolism but Exacerbates Liver Damage in a Piglet Model of Short-Bowel Syndrome.
Pereira-Fantini PM; Lapthorne S; Gahan CGM; Joyce SA; Charles J; Fuller PJ; Bines JE
Cell Mol Gastroenterol Hepatol; 2017 Jul; 4(1):65-74. PubMed ID: 28560290
[TBL] [Abstract][Full Text] [Related]
9. Farnesoid X receptor (FXR): Structures and ligands.
Jiang L; Zhang H; Xiao D; Wei H; Chen Y
Comput Struct Biotechnol J; 2021; 19():2148-2159. PubMed ID: 33995909
[TBL] [Abstract][Full Text] [Related]
10. Potential of Intestine-Selective FXR Modulation for Treatment of Metabolic Disease.
van Zutphen T; Bertolini A; de Vries HD; Bloks VW; de Boer JF; Jonker JW; Kuipers F
Handb Exp Pharmacol; 2019; 256():207-234. PubMed ID: 31236687
[TBL] [Abstract][Full Text] [Related]
11. A novel role for farnesoid X receptor in the bile acid-mediated intestinal glucose homeostasis.
Zhao L; Xuan Z; Song W; Zhang S; Li Z; Song G; Zhu X; Xie H; Zheng S; Song P
J Cell Mol Med; 2020 Nov; 24(21):12848-12861. PubMed ID: 33029898
[TBL] [Abstract][Full Text] [Related]
12. The role of the enterohepatic circulation of bile salts and nuclear hormone receptors in the regulation of cholesterol homeostasis: Bile salts as ligands for nuclear hormone receptors.
Redinger RN
Can J Gastroenterol; 2003 Apr; 17(4):265-71. PubMed ID: 12704471
[TBL] [Abstract][Full Text] [Related]
13. FXR signaling in the enterohepatic system.
Matsubara T; Li F; Gonzalez FJ
Mol Cell Endocrinol; 2013 Apr; 368(1-2):17-29. PubMed ID: 22609541
[TBL] [Abstract][Full Text] [Related]
14. Enterohepatic circulation of bile salts in farnesoid X receptor-deficient mice: efficient intestinal bile salt absorption in the absence of ileal bile acid-binding protein.
Kok T; Hulzebos CV; Wolters H; Havinga R; Agellon LB; Stellaard F; Shan B; Schwarz M; Kuipers F
J Biol Chem; 2003 Oct; 278(43):41930-7. PubMed ID: 12917447
[TBL] [Abstract][Full Text] [Related]
15. Bile salt excretory pump: biology and pathobiology.
Suchy FJ; Ananthanarayanan M
J Pediatr Gastroenterol Nutr; 2006 Jul; 43 Suppl 1():S10-6. PubMed ID: 16819395
[TBL] [Abstract][Full Text] [Related]
16. Progress and challenges of selective Farnesoid X Receptor modulation.
Massafra V; Pellicciari R; Gioiello A; van Mil SWC
Pharmacol Ther; 2018 Nov; 191():162-177. PubMed ID: 29933033
[TBL] [Abstract][Full Text] [Related]
17. The pathophysiological function of non-gastrointestinal farnesoid X receptor.
Yan N; Yan T; Xia Y; Hao H; Wang G; Gonzalez FJ
Pharmacol Ther; 2021 Oct; 226():107867. PubMed ID: 33895191
[TBL] [Abstract][Full Text] [Related]
18. FXR agonist GW4064 improves liver and intestinal pathology and alters bile acid metabolism in rats undergoing small intestinal resection.
Cao Y; Xiao Y; Zhou K; Yan J; Wang P; Yan W; Cai W
Am J Physiol Gastrointest Liver Physiol; 2019 Aug; 317(2):G108-G115. PubMed ID: 30920307
[TBL] [Abstract][Full Text] [Related]
19. Bile acids and their nuclear receptor FXR: Relevance for hepatobiliary and gastrointestinal disease.
Gadaleta RM; van Mil SW; Oldenburg B; Siersema PD; Klomp LW; van Erpecum KJ
Biochim Biophys Acta; 2010 Jul; 1801(7):683-92. PubMed ID: 20399894
[TBL] [Abstract][Full Text] [Related]
20. The expanding role of the bile acid receptor farnesoid X in the intestine and its potential clinical implications.
Ceulemans LJ; Canovai E; Verbeke L; Pirenne J; Farré R
Acta Chir Belg; 2016 Jun; 116(3):156-163. PubMed ID: 27684270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
